Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 10, Issue 1, 2016, Pages 69-76

  McRae, Bradford L ^a   Levin, Alon D ^b   Wildenberg, Manon E ^b   Koelink, Pim J ^b   Bousquet, Peter ^a   Mikaelian, Igor ^a   Sterman, Annette Schwartz ^a   Bryant, Shaughn ^a   D'Haens, Geert ^b   Kamath, Rajesh ^a   Salfeld, Jochen ^a   Van Den Brink, Gijs R ^b  

^a ABBVIE INC   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anti TNF; Fc receptor; IBD

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CELL DEATH; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; INFLAMMATORY BOWEL DISEASE; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BAGG ALBINO MOUSE; COLITIS, ULCERATIVE; CROHN DISEASE; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; RANDOMIZATION; SCID MOUSE; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, EXPERIMENTAL; BIOMARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, SCID; MOLECULAR TARGETED THERAPY; RANDOM ALLOCATION; RECEPTORS, FC; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963756243     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv179     Document Type: Article

References (33)

1. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The charm trial. Gastroenterology 2007;132:52-65
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The accent I randomised trial. Lancet 2002;359:1541-9
3. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody [adalimumab] in Crohn's disease: The classic-I trial. Gastroenterology 2006;130:323-33; quiz 591
4. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42; quiz 64
5. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012;142:1102-11 e2
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody ca2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease CA2 Study Group. N Engl J Med 1997;337:1029-35
7. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
8. Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8
9. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16
10. Van den Brande JMH, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria t-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85
11. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent antiinflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376-92
12. Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor [TNF] induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14? macrophages. Gastroenterology 2011;141:2026-38
13. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factoralpha antibodies induce regulatory macrophages in an fc region-dependent manner. Gastroenterology 2011;140:221-30
14. Vos AC, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012;18:401-8
15. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6
16. Elliott MJ, Feldmann M, Kalden JR, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha [CA2] versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10
17. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann Rheum Dis 2009;68:805-11
18. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
19. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
20. Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: A French retrospective study. Rheumatology [Oxford] 2010;49:1694-8
21. Toussirot É, Houvenagel É, Goëb V, et al. Development of inflammatory bowel disease during anti-TNF-a therapy for inflammatory rheumatic disease: A nationwide series. Joint Bone Spine 2012;79:457-63
22. van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6
23. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNFalpha monoclonal antibody CA2 binds recombinant transmembrane TNFalpha and activates immune effector functions. Cytokine 1995;7:251-9
24. Sandborn WJ, Feagan BG, Radford-Smith G, et al. Cdp571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial. Gut 2004;53:1485-93
25. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
26. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:423-31 e1
27. Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease-a sonic post hoc analysis. Aliment Pharmacol Ther 2015;41:734-46
28. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IGG fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004;19:511-9
29. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IGG fc receptor gene fcgr3a and response to infliximab in Crohn's disease: A subanalysis of the accent I study. Pharmacogenet Genom 2006;16:911-4
30. Moroi R, Endo K, Kinouchi Y, et al. Fcgr3a-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 2013;65:265-71
31. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47
32. Fonseca JE, Edwards JCW, Blades S, Goulding NJ. Macrophage subpopulations in rheumatoid synovium: Reduced CD163 expression in CD4+ t lymphocyte-rich microenvironments. Arthritis Rheum 2002;46:1210-6
33. Vogelpoel LTC, Hansen IS, Rispens T, et al. Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat Commun 2014;5:5444